However, whilst HDAC inhibitors  sodium phenylbutyrate and valproic acid are safe and tolerable in human ALS phase II clinical trials, there was no difference in survival compared to placebo [101].Therapeutic strategies involving preventing protein aggregation and restoring proteostasis have been widely studied in ALS. Here, HDAC9 is linked to amyotrophic lateral sclerosis.